莫沙必利联合聚乙二醇4000治疗慢性功能性便秘疗效观察

目的:观察莫沙必利联合聚乙二醇4000散剂治疗慢性功能性便秘的疗效.方法:117例经确诊的慢性功能性便秘患者随机分为3组,治疗组(A组)52例,给予口服莫沙必利5 ms/次,3次/天,聚乙二醇4000散剂10g/次,2次/天;对照组又分为B组和C组,B组34例,口服莫沙必利5 mg/次,3次,天,C组31例,口服聚乙二醇4000散剂10g/次,20/天,疗程均为15天.治疗后观察患者大便次数、大便形状及大便困难等症状缓解情况.结果:治疗15天后,3组总有效率分别为94.2%,58.8%,74.2%,治疗组与对照组相比较差异有显著性(P＜0.01).结论:莫沙必利联合聚乙二醇4000散剂治疗慢性功能性便秘疗效满意,不良反应少,是目前治疗功能性便秘的可行方案.     

聚乙二醇4000治疗老年患者慢性功能性便秘的疗效分析

目的观察聚乙二醇4000治疗老年患者慢性功能性便秘的疗效和安全性。方法选择慢性功能性便秘老年患者72例,随机平分为治疗组和对照组。治疗组选用聚乙二醇4000治疗,每次10g,bid,疗程2周;对照组选用乳果糖治疗,每次15ml,bid。疗程2周。观察排便次数、性状的变化及伴随症状的情况。结果聚乙二醇4000和乳果糖均可使多数老年慢性功能性便秘患者的大便次数、大便性状及伴随症状恢复正常或缓解,总有效率分别为72．2％和67．7％,两组无显著性差异(P＞0．05),药物不良反应发生率分别为5．6％、11．1％,差异无显著性(P＞0．05)。结论聚乙二醇4000是一种治疗老年患者慢性功能性便秘有效而安全的药物。     

聚乙二醇4000治疗成人慢性功能性便秘的多中心随机对照临床试验研究

目的评价聚乙二醇4000治疗成人慢性功能性便秘的有效性及安全性。方法多中心临床试验以欧车前亲水胶体为对照,采用随机、平行对照的试验方法,试验共入选病例124例,其中入选聚乙二醇4000治疗组64例,临床治疗评价病例63例,安全性评价64例;入选欧车前亲水胶体对照60例,临床疗效评价病例59例,安全性评价60例。聚乙二醇4000和欧车前亲水胶体的剂量分别为10g和6g,每日2次口服,疗程两周。结果聚乙二醇4000与欧车前亲水胶体均可使大部分慢性功能性便秘患者的大便形状、次数恢复正常,主要消化道症状消失,其总有效率相近,分别为85.7%和86.4%,但显效率不同,分别为81.0%及62.7%,差异有显著性（P<0.05）。药物不良反应发生率分别为7.81%和11.7%,二者比较差异无显著性（P>0.05）。结论聚乙二醇4000是治疗慢性功能性便秘的安全、有效药物。     

莫沙必利和聚乙二醇4000治疗小婴儿功能性便秘的临床观察

目的:评价莫沙必利和聚乙二醇4000治疗小婴儿功能性便秘的临床疗效.方法:2006年5月～2007年10月本院儿科门诊诊断为婴儿功能性便秘患儿32例,予口服莫沙必利0.6 mg/(kg·d),分3次口服,聚乙二醇4000散剂0.25～0.3 g/(kg·d),分2次在早、晚冲服,疗程5～7 d.结果:3 d内排便正常21例(65.62%),3～5 d排便正常5例(15.62%),5～7 d排便正常4例(1.25%),无效2例(6.25%),总有效率93.75%,未发现明显不良反应.结论:莫沙必利和聚乙二醇4000治疗小婴儿功能性便秘效果显著,有临床应用价值.     

聚乙二醇4000散与舒肝解郁胶囊联合治疗功能性便秘的临床评价

目的观察聚乙二醇4000散联合舒肝解郁胶囊治疗功能性便秘的疗效及安全性。方法 96例符合功能性便秘诊断标准的患者随机分成两组,共观察4周。A组予以聚乙二醇4000散口服,B组予以口服聚乙二醇4000散同时口服舒肝解郁胶囊治疗。所有患者均采用Bristol粪便性状评分(Bristol stool scale,BSC)评估便秘情况和汉密尔顿抑郁量表-17(HAMD-17)及汉密尔顿焦虑量表(HAMA)进行心理测评,分别于0周、1周、2周、4周进行评分,分析对比两种治疗方式对上述指标变化以判断各自疗效。结果两组患者的基线特征以及BSC、HAMD-17、HAMA评分无明显差异。但随着治疗时间的延长,两组患者各自评分都呈明显下降趋势(P<0.01);聚乙二醇4000散联合舒肝解郁胶囊组患者各评分较单纯使用聚乙二醇4000散组下降更加明显且在第2周开始出现有统计学意义变化(P<0.01);两组患者均无严重不良反应。结论聚乙二醇4000散联合舒肝解郁胶囊治疗功能性便秘不但能显著改善便秘症状,还可以改善患者焦虑抑郁症状,从而使得患者生活质量较以往有较大提高,适合临床推广应用。     

双歧三联活菌联合聚乙二醇4000散剂治疗成人功能性便秘29例

目的观察双歧三联活菌联合聚乙二醇4000散剂（福松冲剂）治疗成人功能性便秘的临床疗效。方法将门诊成人功能性便秘患者85例随机分为3组,A组：29例,双歧三联活菌每次420mg,bid,po,聚乙二醇4000散剂每次10g,bid,po;B组：28例,双歧三联活菌胶囊每次420mg,bid,po;C组：28例,聚乙二醇4000散剂每次10g,bid,po。4周后,复查肝肾功能,记录不良反应及排便次数和恢复情况变化并做对比分析。结果患者服用4周后,双歧三联活菌联合聚乙二醇4000散剂组明显优于单用双歧三联活菌组和聚乙二醇4000散剂组,未发现不良反应。结论双歧三联活菌联合聚乙二醇4000散剂治疗成人功能性便秘疗效确切,耐受性好,是一种比较可行的临床治疗方案。     

聚乙二醇4000散治疗功能性便秘的临床分析

目的便秘的发病率越来越高,已严重影响了现代人的生活质量。治疗功能性便秘除了改善生活方式和健康饮食以外,主要的治疗方法仍然以药物治疗为主。聚乙二醇4000散是一种新型的渗透性泻药,其作用日益受到重视。方法选取功能性便秘患者分别给予聚乙二醇4000散及乳果糖治疗,观察治疗效果。结果实验组：显效21例,占52.5%;有效18例,占45.0%;无效1例,占2.5%。对照组：显效12例,占30.8%;有效20例,占51.3%;无效7例,占17.9%;有1例患者不能耐受腹痛而停药。结论聚乙二醇4000散治疗便秘的作用优于乳果糖,可明显缓解便秘患者的症状,且不良反应较小。而且便秘患者不能滥用泻药,应在医生指导下正确选用。     

莫沙必利联合聚乙二醇4000治疗糖尿病合并便秘的疗效观察

目的评价莫沙必利联合聚乙二醇4000治疗糖尿病合并便秘的疗效。方法选取2008—2010年我院糖尿病门诊收治的糖尿病合并便秘患者112例,给予莫沙必利5mg,3次/d+聚乙二醇4000 10g,2次/d,口服;分别于第2周和第4周观察患者治疗情况和药物不良反应。结果服药后起效时间为2～5d,平均3.2d。治疗第2周显效51例(45.54%),有效40例(35.71%),无效21例(18.75%),总有效率为81.25%。治疗第4周显效87例(77.68%),有效22例(19.64%),无效3例(2.68%),总有效率为97.32%。均无严重不良反应发生。结论莫沙必利联合聚乙二醇4000治疗糖尿病合并便秘安全、有效。     

复方聚乙二醇电解质散治疗慢性功能性便秘的临床观察

目的：评价复方聚乙二醇电解质散治疗慢性功能性便秘的临床效果。方法：83例慢性功能性便秘患者随机分为试验组43例和对照组40例,分别口服复方聚乙二醇电解质散和乳果糖,bid,早晚餐前服用,治疗4周。结果：两组治疗后排便次教均明显增加,大便性状及伴随症状明显改善,均未出现明显不良反应。试验组总有效率及症状改善情况明显较优（P〈0．05）。结论：复方聚乙二醇电解质散治疗慢性功能性便秘疗效较为理想。     

Clinical efficacy and safety of polyethylene glycol 3350 versus liquid paraffin in the treatment of pediatric functional constipation

BACKGROUND AND THE PURPOSE OF THE STUDY: Functional constipation is prevalent in children. Recently polyethylene glycol has been introduced as an effective and safe drug to treat chronic constipation. There are only a few clinical trials on comparison of PEG and liquid paraffin in childhood constipation. The purpose of this study was to evaluate clinical efficacy and safety of PEG 3350 solution and liquid paraffin in the treatment of children with functional constipation in Sari Toba clinic during the period of 2008-2009. METHODS: Children with a history of functional constipation were subjects of this study. One hundred and sixty children of 2-12 years old with functional constipation were randomized in two PEG and paraffin treatment groups. Patients received either 1.0-1.5 g/kg/day PEG 3350 or 1.0-1.5 ml/kg/day liquid paraffin for 4 months. Clinical efficacy was evaluated by stool and encopresis frequency/week and overall treatment success rate was compared in two groups. RESULTS AND MAJOR CONCLUSION: Compared with the baseline, defecation frequency/ week increased significantly and encopresis frequency meaningfully decreased in two groups during the period of the study. Patients using PEG 3350 had more success rate (mean: 95.3%±3.7) compared with the patients in paraffin group (mean: 87.2%±7.1) (p=0.087). Administration of PEG 3350 were associated with less adverse events than liquid paraffin. In conclusion in treatment of pediatric functional constipation, regarding clinical efficacy and safety, PEG 3350 were at least as effective as liquid paraffin and but less adverse drug events.     

聚乙二醇3350治疗成人慢性功能性便秘的多中心随机对照的临床研究

目的观察聚乙二醇3350(默维可,Movical)治疗成人慢性功能性便秘的疗效及安全性.方法采用多中心随机平行对照试验,按照试验中心分层,按入选标准选择成人便秘患者126例,随机进入试验组和对照组,2组均为63例.选择欧车前亲水胶(恺司尔,Konsyl)作为试验对照药.试验组服用聚乙二醇3350 13.7g*d-1,bid;对照组服用欧车前亲水胶 3.5g*d-1,bid;疗程2周.结果2组患者经治疗后便秘伴随症状如腹痛、腹胀、排便困难、排便疼痛等均得到缓解.均未造成服药后电解质丢失,2组结果近似,服药后试验组及对照组大便形状复常率为87.30%和66.67%,总有效率为92.07%和73.02%,大便性状恢复正常、总有效率及首次排便时间试验组均优于对照组(P<0.01).在安全性研究中,除对照组1例ALT升高外,其余均未发现明显不良反应.结论聚乙二醇3350治疗成人慢性功能性便秘安全、有效.     

聚乙二醇4000散剂联合枸橼酸莫沙必利分散片治疗便秘

目的为了进一步研究临床治疗便秘的过程中采用聚乙二醇4000散剂联合枸橼酸莫沙必利进行治疗的优势,从而为临床便秘的治疗提供借鉴之据。方法选取笔者所在医院2010-12-2012-12收治的便秘患者124例,随机分成联合用药组和单药组,每组62例。联合用药组患者予聚乙二醇4000散剂和枸橼酸莫沙必利分散片进行治疗,单药组患者予枸橼酸莫沙必利分散片进行治疗,观察比较两组患者实施不同治疗方法后的临床治疗效果。结果两组患者实施不同药物治疗后,联合用药组的62例患者中,总有效61例占98.39%;单药组的62例患者中,总有效29例占46.77%。两组患者总有效率比较,联合用药组显著高于单药组(P<0.05)。结论在临床治疗便秘的实践过程中,采用聚乙二醇4000散剂联合枸橼酸莫沙必利分散片的治疗效果更优,是临床治疗便秘的安全可靠选择。     

聚乙二醇洛塞那肽治疗2型糖尿病的有效性和安全性系统评价

目的:系统评估聚乙二醇洛塞那肽(PEX168)在中国2型糖尿病(T2DM)患者中的疗效和安全性,为临床用药提供循证学依据.方法:计算机检索从建库至2021年3月31日的Cochrane Library、ClinicalTrails、Embase、Medline、PubMed、CNKI、万方、维普等数据库,检索聚PEX1...     

聚乙二醇4000治疗老年人慢性功能性便秘

目的 :评价聚乙二醇 40 0 0对老年人慢性功能性便秘的疗效和安全性。方法 :60例年龄在(81±s 5)a的老年功能性便秘病人 ,分为 2组 ,共有 59例病人完成治疗 ,聚乙二醇组 2 9例给予聚乙二醇 40 0 0 ,1 0g,po,bid ;乳果糖组 30例 ,给以乳果糖 ,1 5mL ,po,bid ,疗程均为 2 1d。治疗后观察病人大便次数和大便形状 ,并观察腹胀、食欲不振、大便困难等症状缓解率。结果 :聚乙二醇组经治疗后排便困难发生率由 86 %下降至 34 % ,较治疗前有显著性下降 (P <0 .0 1 ) ,与乳果糖组比较 ,无统计学差异 (P >0 .0 5) ;且在有效病人中服药量小于乳果糖组 ,但 2组相比无统计学差异 ;聚乙二醇组治疗便秘的显效率和有效率分别为 52 %和 1 7% ,与乳果糖组相似 (P >0 .0 5) ;而不良反应发生率为 6 .9% ,与乳果糖组相近 (P >0 .0 5)。结论 :聚乙二醇 40 0 0能安全有效地治疗老年人慢性功能性便秘     

Preparation and evaluation of immediate release ibuprofen solid dispersions using polyethylene glycol 4000

To improve its dissolution, ibuprofen solid dispersions (SDs) were prepared in a relatively easy and simple manner, characterized by scanning electron microscopy (SEM), differential scanning calorimetry (DSC) and Fourier transform infrared spectroscopy (FT-IR), and evaluated for solubility, in-vitro drug release and oral bioavailability of ibuprofen in rats. Loss of individual surface properties during melting and resolidification as revealed by SEM micrographs indicated the formation of effective SDs. Absence or shifting towards the lower melting temperature of the drug peak in SDs and physical mixtures in DSC study indicated the possibilities of drug-polymer interactions. FT-IR spectra showed the presence of drug crystalline in SDs. Quicker release of ibuprofen from SDs in rat intestine resulted in a significant increase in AUC and Cmax, and a significant decrease in Tmax over pure ibuprofen. Preliminary results from this study suggested that the preparation of fast dissolving ibuprofen SDs by low temperature melting method using polyethylene glycol 4000 (PEG 4000) as a meltable hydrophilic polymer carrier could be a promising approach to improve solubility, dissolution and absorption rate of ibuprofen.     

Comparison of efficacy and safety of two doses of two different polyethylene glycol-based laxatives in the treatment of constipation

AIM: To compare standard and maximum daily doses of polyethylene glycol 3350 plus electrolytes (Transipeg) and polyethylene glycol 4000 (Forlax) in a multicentre, double-blind, randomized, parallel-group study. METHODS: Ambulatory patients with idiopathic chronic constipation were randomized to receive Forlax (10 or 20 g) or Transipeg (5.9 or 11.8 g) for 1 month. The primary efficacy end-point was stool frequency. Secondary efficacy parameters included stool consistency, date of occurrence of first motion, straining on defecation, rectal evacuation, abdominal pain and distension. Adverse events were recorded. RESULTS: Stool frequency was significantly increased compared with baseline in all treatment groups (P = 0.0001). Most patients (> or = 67.3%) had their first stool within 1 day of starting treatment. Stool consistency significantly improved compared with baseline in all treatment groups (P = 0.0001). The percentage of patients with normal stool consistency was significantly higher for standard-dose Transipeg vs. both maximum-dose treatments (P < 0.01). Other secondary parameters were also significantly improved compared with baseline in all treatment groups (P = 0.0001). All medications were well tolerated. CONCLUSIONS: Standard-dose Transipeg (5.9 g) normalized stool consistency with less semi-liquid or liquid stools than maximum-dose Transipeg and Forlax, with a non-significant trend towards less semi-liquid or liquid stools than standard-dose Forlax.     

左乙拉西坦单药治疗癫痫的临床疗效和安全性评价

目的探讨左乙拉西坦单药治疗癫痫的临床疗效和安全性。方法选择2014年12月至2016年12月本院收治的癫痫患者作为研究资料,共64例均接受左乙拉西坦单药治疗,回顾性分析治疗6个月后的临床疗效及不良反应发生情况。结果 s CTCS发作类型治疗后发作频率明显低于SPS、CPS、CTCS三种类型,t=2.11,t=3.92,t=3.29,P<0.05;而s CTCS发作类型应答率则显著高于SPS、CPS、CTCS三种类型,χ~2=3.88,χ~2=4.10,χ~2=7.12,P<0.05;不良事件发生率为10.9%。结论对癫痫患者采用左乙拉西坦单药治疗具有良好的治疗效果,且具有较好的耐受性,安全性较高,值得推广应用。     

马来酸曲美布汀胶囊联合聚乙二醇4000散治疗便秘型肠易激综合征的疗效观察

目的观察马来酸曲美布汀胶囊联合聚乙二醇4000散治疗便秘型肠易激综合征的疗效及安全性。方法 104例符合罗马Ⅲ标准的便秘型肠易激综合征患者随机分为2组。治疗组54例:马来酸曲美布汀胶囊0.2g/次,3次/d,联合聚乙二醇4000散10g/次,加水300~400mL服用,2次/d;对照组50例:马来酸曲美布汀0.2g/次,3次/d,疗程均为4周。结果治疗组与对照组相比,腹部症状(腹痛、腹胀)缓解总有效率分别为96%,90%。2组粪便性状分型均有明显改善,治疗组腹部症状及便秘的改善比对照组更为明显,差异有统计学意义(P<0.05)。2组不良反应差异无统计学意义。结论马来酸曲美布汀胶囊联合聚乙二醇4000散治疗便秘型肠易激综合征有效、安全,值得临床应用。